Hypertension Control With Isradipine - One year follow up
Article Sidebar
Main Article Content
Abstract
Isradipine, a new calcium channel blocker, was evaluated in a clinical trial spanning one year. The results of 50 patients are presented. The systolic BP showed a reduction of 30mmHg from the initial to the final visit. The diastolic BP showed a reduction of 21mmHg from the initial to the final visit. A very benign side effect profile was encountered during the study. Overall, Isradipine has proved to be an effective and safe antihypertensive agent in mild to moderate essential hypertension.
Article Details
How to Cite
1.
Zaidi EH. Hypertension Control With Isradipine - One year follow up. J Postgrad Med Inst [Internet]. 2011 Aug. 29 [cited 2024 Nov. 23];10(1). Available from: https://jpmi.org.pk/index.php/jpmi/article/view/524
Issue
Section
Original Article
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.